Lung Cancer

Andrew Ciupek, from the GO2 Foundation for Lung Cancer, discusses what is on the horizon for patients with small cell lung cancer.

 

Andrew Ciupek, from the GO2 Foundation for Lung Cancer, talks about the increasing amount of targeted therapies available for patients with non-small cell lung cancer, and why clinical trials are vital in increasing the amount available to those with the disease.
 

The Food and Drug Administration approved Imfinzi in combination with certain standard-of-care chemotherapies in extensive-stage small cell lung cancer, as the therapy improves median overall survival.
 

Researchers suggest that patients with advanced non-small cell lung cancer who have limited daily functions should be better educated about therapy decisions.
 

Here is a list of the recent trial initiations that occurred within the cancer space in March.
 

Combining immunotherapies with chemotherapy has shown improved survival in patients with extensive-stage small cell lung cancer.
 

Final results of the phase 3 CASPIAN trial show that Imfinzi (durvalumab) in combination with a choice of standard-of-care chemotherapies demonstrates a sustained overall survival benefit in patients with extensive-stage small cell lung cancer.

Small cell lung cancer often becomes resistant to chemotherapy, and recent research highlights that these cells evolve, explaining why patients require further lines of treatment.
 

In this episode of the “CURE Talks Cancer” podcast, we spoke with Andrew Ciupek, from the Go2 Foundation for Lung Cancer, on the importance of biomarker testing and targeted therapy options for patients with non-small cell lung cancer.

The combination of Keytruda plus chemoradiotherapy induced a ‘promising’ 12-month progression-free survival rate in patients with locally advanced non-small cell lung cancer.